Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-No bubble in tech?

Thu, 17th Sep 2020 10:41

* European shares open lower: STOXX down 0.6%

* Fed fails cheer investors

* BoE in focus, no change expected

* Unibail-Rodamco drops on capital strengthening move
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni
(danilo.masoni@thomsonreuters.com) and Stefano Rebaudo (stefano.rebaudo@thomsonreuters.com) in
Milan.

NO BUBBLE IN TECH? (0937 GMT)

The tech bubble dilemma has been the talk of town for months. At the beginning of September
the Nasdaq was at an all-time high but only three weeks later a sharp correction has wiped off
around 1,000 points from the tech-heavy U.S. index.

Software has been Credit Suisse's largest overweight for the last decade but now the Swiss
bank reduced the size of its overweight saying that "excess in tech is high" though "in most
instances not extreme."

Fund managers recently surveyed by BoFA sounded a bit more cautious. For them the "tech
bubble" is now the second biggest tail risk after COVID-19 second wave.

But valuation metrics would suggest we're still far from bubble territory, according to
Credit Suisse. Bubbles have re-rated to a P/E ratio of 45-72 times and the Nasdaq is currently
on 37 times, it says in a research note.

The Swiss bank still recommends being overweight because tech is defensive, cyclical into an
upturn, growth-oriented and will likely benefit from a weak dollar.

Even though it cut software to overweight from strong overweight it remains "very positive"
on Microsoft and SAP. It has a small overweight on semis and likes gaming
stocks.

Despite the broadly positive stance, Credit Suisse warns that a COVID-19 vaccine "could
cause a short-term reversal in some of the online trends and would help other sectors" such as
financials and leisure.

(Stefano Rebaudo)

*****

EUROPE AT THE OPEN: ALL DOWN BUT WITHIN RANGES (0717 GMT)

Europe is literally painted red this morning with the STOXX 600 and all sub-sectors
posting losses in early deals after the Fed failed to provide fresh reasons to cheer.

Autos, banks and miners are sliding over 2% while tech is down 1.6%.

Despite the undistinguished sell-off, main indexes aren't breaking any new ground, the STOXX
is just giving up two days of gains and it remains anchored within its recent trading range.

Top faller is shopping centres landlord Unibail-Rodamco down 8% after it announced
a 9.0 billion euro plan to strengthen its finances. IG Group and Next are among the few stocks
on the up after well-received trading updates.

Here's your snapshot:

(Danilo Masoni)

*****

ON OUR RADAR: CENTRAL BANKS, BALANCE SHEETS AND TECH TROUBLES (0637GMT)

Futures in Europe are pointing to falls of more than 1% as investors digest a number of
central bank meetings, starting from the Fed which failed to offer any new reason to cheer, and
fresh heavy falls in U.S. tech stocks.

Earlier this morning the BoJ kept monetary policy steady and slightly upgraded its view on
the economy, while later on the BoE is expected to signal that it is getting ready to pump yet
more stimulus into Britain's economy.

Euro STOXX 50 futures were last down 1.3% and FTSE 100 futures fell 1% following a tech-led
sell off on Wall Street overnight. Nasdaq futures were down nearly 2%.

On the corporate front a few companies are taking steps to strengthen their balance sheets.

Shopping centres landlord Unibail-Rodamco announced 9.0 billion euros plan to
strengthen its finances that includes a 3.5 billion capital increase along with curbs to cash
dividends and non-essential capex.

In the UK, Rolls-Royce said it continued to review funding options, including debt
and equity, to boost its balance sheet, while the world's largest holiday company
TUI is planning a share sale to raise up to 1 billion euros, according to people
close to the matter.

In more upbeat news, Delivery Hero shares could rise after news it will buy the
Latin American operations of Glovo for up to 230 million euros.

Next raised its profit outlook for the second time in two months as the British
clothing retailer reported strong recent trading.

Eyes also on Spanish banks with Caixabank and Bankia set to approve a
deal today that will create Spain's biggest domestic lender.

Meanwhile on the COVID-19 front, there are no signs of the global pandemic slowing
but more positively an Oxford University document said the adverse events that led
to a pause in trials evaluating AstraZeneca vaccine candidate may not have been
associated with the vaccine itself.

(Danilo Masoni)

*****

MORNING CALL: EUROPE SEEN LOWER POST-FED (0529 GMT)

European shares are expected to open lower this morning with futures on the Euro STOXX 500
falling almost 1% following losses on a tech-led sell-off at Wall Street overnight and after the
Federal Reserve took no new policy action.

The U.S. central bank kept interest rates pinned near zero and promised to keep them there
until inflation is on track to "moderately exceed" its 2% inflation target "for some time."

Over in Asia, MSCI's broadest index of Asia-Pacific shares outside Japan was
down 1.1%, running out of steam after five straight days of gains. Japan's Nikkei shed
0.6%.

(Danilo Masoni)

*****

More News
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.